Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $4.13 USD
Change Today -0.01 / -0.24%
Volume 257.2K
BCLI On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ CM
As of 8:10 PM 04/27/15 All times are local (Market data is delayed by at least 15 minutes).

brainstorm cell therapeutics (BCLI) Snapshot

Open
$4.17
Previous Close
$4.14
Day High
$4.37
Day Low
$4.10
52 Week High
01/2/15 - $8.47
52 Week Low
12/12/14 - $2.81
Market Cap
76.0M
Average Volume 10 Days
1.1M
EPS TTM
$-0.64
Shares Outstanding
18.4M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for BRAINSTORM CELL THERAPEUTICS (BCLI)

brainstorm cell therapeutics (BCLI) Related Bloomberg News

View More Bloomberg News

brainstorm cell therapeutics (BCLI) Related Businessweek News

No Related Businessweek News Found

brainstorm cell therapeutics (BCLI) Details

Brainstorm Cell Therapeutics Inc., a biotechnology company, develops adult stem cell therapies for neurodegenerative disorders, such as amyotrophic lateral sclerosis, multiple sclerosis, and Parkinson’s disease. It holds the rights to develop and commercialize its NurOwn technology through licensing agreement with Ramot of Tel Aviv University Ltd. The company’s NurOwn technology is based on a novel differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells and secreting cells that release neurotrophic factors, including glial-derived neurotrophic factor, brain-derived neurotrophic factor, vascular endothelial growth factor, and hepatocyte growth factor for the growth, survival, and differentiation of developing neurons. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004 to reflect its new line of business in the development of novel cell therapies for neurodegenerative diseases. Brainstorm Cell Therapeutics was founded in 2000 and is headquartered in Hackensack, New Jersey.

16 Employees
Last Reported Date: 03/26/15
Founded in 2000

brainstorm cell therapeutics (BCLI) Top Compensated Officers

President
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: $106.0K
Compensation as of Fiscal Year 2013.

brainstorm cell therapeutics (BCLI) Key Developments

BrainStorm Cell Therapeutics Inc. Presents Results from Phase 2a Study of NurOwn in Amyotrophic Lateral Sclerosis

BrainStorm Cell Therapeutics Inc. is presenting results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) at a poster session on April 21, 2015 at the American Academy of Neurology annual meeting, taking place in Washington D.C. Among the new results is a piecewise linear regression analysis of all subjects who received intrathecal (IT) administration in the phase 2a study and the prior phase 1/2 study. At six months post-treatment, there was a statistically significant improvement in the estimated rate of decline in Forced Vital Capacity (FVC), from -5.1% per month pre-treatment to -1.2% per month post-treatment (two-sided p=0.036) and a nearly significant improvement in the rate of ALS Functional Rating Score-Revised (ALSFRS-R) decline, from -1.2 points per month pre-treatment to -0.6 points per month post treatment (two-sided p=0.052). Also being reported for the first time are local positive effects of intramuscular administration. 3D volumetric analysis using MRI revealed an improvement in the rate of decline in muscle mass in the right arm, the site of NurOwn® administration, through one month post-treatment, as compared to the left arm. Electromyography demonstrated a trend of stabilization of the compound motor axon potential in the right musculocutaneous nerve as compared to deterioration observed in the left.

BrainStorm Cell Therapeutics to Present Positive NurOwn® Phase 2a Clinical Data at American Academy of Neurology Annual Meeting

BrainStorm Cell Therapeutics Inc. announced that results from its phase 2a study of NurOwn® in amyotrophic lateral sclerosis (ALS) and additional analyses will be presented at the American Academy of Neurology annual meeting, taking place in Washington D.C. from April 18 to 25, 2015. NurOwn® is an autologous cell therapy in which bone marrow-derived mesenchymal stem cells are expanded and then, under proprietary conditions, induced to secrete several neurotrophic factors known to promote neuronal survival. BrainStorm has completed two clinical trials of these neurotrophic factor-secreting mesenchymal stem cells in Israel, and is currently enrolling a randomized, double-blind, placebo-controlled phase 2 study at three centers in the United States.

Brainstorm Cell Therapeutics Inc. Announces Consolidated Earnings Results for the Fourth Quarter and Year Ended December 31, 2014

Brainstorm Cell Therapeutics Inc. announced consolidated earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported operating loss of $2,666,000 against $1,382,000 a year ago. Pre-Tax Loss was $2,730,000 against $1,217,000 a year ago. Net loss was $2,730,000 or $0.18 per basic and diluted net loss per share from continuing operations compared to $1,217,000 or $0.10 per basic and diluted net loss per share from continuing operations a year ago. For the year, the company reported operating loss of $7,421,000 against $5,043,000 a year ago. Pre-Tax Loss was $9,246,000 against $4,899,000 a year ago. Net loss was $9,246,000 or $0.68 per basic and diluted net loss per share from continuing operations compared to $4,899,000 or $0.46 per basic and diluted net loss per share from continuing operations a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
BCLI:US $4.13 USD -0.01

BCLI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for BCLI.
View Industry Companies
 

Industry Analysis

BCLI

Industry Average

Valuation BCLI Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 9.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BRAINSTORM CELL THERAPEUTICS, please visit www.brainstorm-cell.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.